Key Highlights:
Talicia^® approved by the FDA for the treatment of H. pylori infection in adults; U.S. launch with RedHill’s sales force expected by mid-March 2020
 Acquisition of global rights to Movantik^® (naloxegol) for the treatment of opioid-induced constipation (OIC) in adults from AstraZeneca, subject to certain closing conditions and regulatory clearances; Movantik^® generated U.S. net sales of $96 million in 2019
 
Bay Street News